Centre Henri-Becquerel

Rouen, Haute-normandie 76038

0 studies enrolling now · 6 studies all time

What they study most

Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Indolent Non-Hodgkin's Lymphomas, Leukemia, Myeloid, Acute, Multiple Myeloma, Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Relapsed/Refractory Follicular Lymphoma

Studies at this site

• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. — Running, not enrolling
• Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies — Completed
• SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction — Completed
• TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Stopped early
• Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients — Completed
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas — Stopped early